SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Litecoin is a decentralized, peer-to-peer digital currency designed to enable instant, near-zero cost payments to individuals and merchants worldwide. As an open-source global payment network that functions independently of central banks or intermediaries, its main value proposition lies in providing a scarce digital asset with a fixed maximum supply of 84 million tokens.  The network operates using a Proof of Work mechanism where computers solve complex puzzles to confirm transactions and secure the blockchain. It is distinguished by a block generation time of 2.5 minutes, which allows for faster transaction confirmations and a higher total throughput than earlier protocols. Key technical features include the Scrypt hashing algorithm, which promotes wider network participation, and MimbleWimble Extension Blocks, which improve user privacy by allowing transaction details to be hidden.  The LTC token is used for settling global payments, executing microtransactions through smaller units called litoshis, and diversifying digital portfolios with a highly liquid asset. New tokens are issued to miners as rewards for verifying blocks, though these rewards undergo a halving event approximately every four years to strictly control inflation. This process ensures the ledger maintains immutability, meaning records cannot be changed once they are saved to the global network.  Created by former Google engineer Charlie Lee, the project is supported by the Litecoin Foundation, a non-profit organization dedicated to ecosystem adoption. Unlike many venture-backed projects, it is maintained by a decentralized community of independent developers and a global network of miners. The project has seen recent institutional adoption, with entities like Lite Strategy and Luxxfolio Holdings adding significant amounts of LTC to their corporate treasuries as of late 2025.

Litecoin

Litecoin is trending as investors debate its role as "digital silver" amid potential institutional interest and the upcoming launch of network upgrades like LitVM. While some community members remain skeptical of its long-term performance compared to newer assets, others are actively accumulating the coin, citing its reliability and potential for catch-up growth in a bull market.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Summit Therapeutics is trending as investors focus on the company's progress with ivonescimab, specifically highlighting its potential as a disruptor in the lung cancer treatment landscape ahead of its upcoming PDUFA date. The community is actively debating the company's reliance on clinical data from China while closely watching for trial readouts that could influence its competitive standing against established market leaders.

Onboarding the first billion gamers into Web3.

Portal

Market sentiment surrounding Portal is deeply divided, with vocal traders debating whether the asset is a sleeping giant poised for aggressive growth or a potential high-risk volatility trap. Discussions focus heavily on aggressive accumulation strategies and technical chart patterns, even as skeptics voice concerns regarding the project's long-term sustainability.

Bombardier, Inc. engages in the design, building, and maintenance of aircraft. It operates through the Business Aircraft and Others segments. The Business Aircraft segment is involved in selling new aircraft, pre-owned aircraft, and defense aircraft, as well as services and support including parts, smart services, service centers, training, and technical publications. The Others segment refers to the sale of components related to commercial aircraft programs. The company was founded on June 19, 1902 and is headquartered in Dorval, Canada.

Bombardier Inc. - Ordinary Shares - Class B (Sub Voting)

Bombardier Cl B Sv

Bombardier is trending as the community highlights strong Q1 2026 financial results, including significant backlog growth and a raised free cash flow guidance. Investors are actively discussing the potential for a stock split and the company's strategic positioning in securing military contracts, such as the GlobalEye system for NATO.

This has been pretty requested, so here's a short explainer of what $Staccana is:  @STACCoverflow has cooked up a Solana fork using some tech that was created, but never utilized since Solana cannot rollback or change inherent promises the chain makes. Here are the promises that Staccana chain makes:  a. Token transfers are encrypted by default b. Launches use frequent-batch auctions (MEV is not possible on this chain)  I've been coordinating with Stacc to help create a flywheel for this meme coin and the native ssSOL token. If you want early access to the chain, best rewards, and to become a part of this ecosystem you want to be invested in $Staccana.  Said flywheel is being cooked by Stacc as we speak, and the plan is to release Staccana main net on May 16th. I will be contributing the locked 4.6% supply to LPs for the flywheel.  Creator fees will be used to bootstrap the network, incentivize early users, and to add to the Stacanna treasury.  73edX6xoGY4v5y2hzuKdrUbJXLntqgmo74au1Ki1pump

Solana Fork Staccana

The Solana fork Staccana is gaining traction as investors anticipate its upcoming mainnet launch, which promises to integrate privacy-focused infrastructure into the existing blockchain ecosystem. While some community members are skeptical, proponents emphasize the project's consistent development and potential as an early-stage opportunity within the liquid staking and privacy narratives.

Pulse Biosciences, Inc. operates as an immuno-oncology company developing a proprietary oncolytic electroceutical therapy based on its Nano Pulse Stimulation (NPS) technology. It manufactures surgical and medical instruments using a novel and proprietary platform technology called Nano-Pulse Electro-Signaling. The NPES provides local tumor control and initiates an adaptive immune response with a vaccine-like effect by inducing immunogenic apoptosis of the cells. The company was founded on May 19, 2014 and is headquartered in Miami, FL.

Pulse Biosciences Inc

Pulse Biosciences is capturing investor attention as the company advances its proprietary nanosecond pulsed field ablation technology for cardiac and soft tissue applications, with community discussions largely focused on significant insider buying and potential future buyout scenarios. Recent volatility and momentum have been further fueled by speculative interest in upcoming clinical data and the company's strategic shift toward high-impact medical device markets.

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Revolution Medicines Inc

Revolution Medicines is trending after reports surfaced that merger negotiations with Merck stalled due to valuation disagreements, cooling immediate buyout speculation. Despite the stock's pullback, the community remains intensely focused on the company's upcoming Phase 3 data and its long-term potential as a premier oncology asset with blockbuster prospects.

SPACEX4200 ($SPCX) is the original and first $SPCX memecoin across all chains, launched on Ethereum in November 2024. Born from the community's enthusiasm for space exploration and humanity's multi-planetary future, $SPCX has built a passionate holder base of space enthusiasts and crypto degens alike.   With the macro backdrop of SpaceX's highly anticipated public listing and the $SPCX ticker becoming available on traditional markets, the community sees this as more than just another memecoin—it's a cultural moment. The token boasts strong holder conviction, with approximately 35-40% of supply in diamond hands.   Independent, community-driven, and fueled by cosmic ambition, $SPCX represents the intersection of space culture and crypto culture. No affiliation with SpaceX or Elon Musk—just a community reaching for the stars.

Paimon SpaceX SPV Token

The community is actively discussing the highly anticipated SpaceX IPO, which is fueling intense speculation regarding its projected multi-trillion dollar valuation and the potential liquidity impacts on broader markets. Investors are closely monitoring both the direct offering and the resulting sympathy moves in space-sector proxies, while expressing caution over the company's aggressive pricing and the potential for a hype-driven retail frenzy.

Venice boasts an innovative approach to generative AI with its unique privacy architecture, access to competitive features including multiple leading open-source LLM models such as DeepSeek R1, PDFs analysis, and image and code generation. An unrestricted AI Characters feature is available with its Pro version, Venice Pro.   VVV is designed to minimize friction and reduce costs for AI agents and developers to access private, reliable, on-demand and perpetual AI inference via Venice.ai's API.

Venice Token

Venice Token (VVV) is experiencing heightened community interest driven by its integration into the AI narrative and recent tokenomics adjustments, including supply reduction and burn initiatives. Investors are actively discussing its potential for volatility due to low circulating supply, while many monitor technical support levels as the project aims to establish a foothold in the decentralized AI infrastructure space.

DEGEN is a reward token for Farcaster users, born from meme culture. It features a unique tipping system that allows the community to reward high-quality content creators. DEGEN also powers the Degen Chain, one of the pioneering Layer 3s launched on Base. Known as the “Las Vegas of blockchains,” it provides a platform for building and using Degen apps, offering a space for fun, innovation, and community-driven experiences.

Degen

Degen is trending as investors debate the potential for a recovery, with community sentiment split between those viewing the project as a long-term utility play and those concerned about insider activity. Discussions center on the upcoming app launch, token burn programs, and hopes for major exchange listings, while participants heavily monitor Base network developments and historical chart patterns for signs of a turnaround.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$RVPH Next step is the very short / small bioequivalance study for the FDA - Once proven, the FDA greenlights the use of it in the second P3.    That&#39;ll be the first major catalyst and (hopeful) rerating of the stock;   Then enrollment &gt; Sometime during the process, I&#39;d expect to see a partnership announcement;  A novel p3 CNS compound with potentially a 15+ year patent is a very attractive asset.    Its gonna be a VERY interesting 12 months.

Stefan Melanscheg

Rahb

Andy Cessna

Toni Dewada

C45_t

KingKongBundee

Bobe Lenoverk

Gebinator

StockTwits Web

Reviva Pharmaceuticals Holdings Inc.

 Next step is the very short / small bioequivalance study for the FDA - Once proven, the FDA greenlights the use of it in the second P3.    That'll be the first major catalyst and (hopeful) rerating of the stock;   Then enrollment > Sometime during the process, I'd expect to see a partnership announcement;  A novel p3 CNS compound with potentially a 15+ year patent is a very attractive asset.    Its gonna be a VERY interesting 12 months.